Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Active, not recruiting · NCT03229200 · Registry updated 2025-10-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | B-cell neoplasm, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, graft versus host disease, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 4 | 2025-10-30 | NCT03229200 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Biotech, Inc., including Johnson & Johnson | 1 |
| Pharmacyclics Switzerland GmbH | 1 |
98 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.